. . "For the treatment of scleroderma, cancer, and restenosis."@en . . . . . "Humans and other mammals"@en . "Readily bioavailable and rapidly absorbed following oral administration."@en . "Halofuginone"@en . "Protozoa"@en . "Halofuginone is a low molecular weight quinazolinone alkaloid, and a potent inhibitor of collagen alpha1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. Halofuginone also effectively suppresses tumor progression and metastasis in mice."@en . . "Tempostatin (Collgard Biopharmaceuticals)"@en . "55837-20-2"@en . . . "# Elkin M, Miao HQ, Nagler A, Aingorn E, Reich R, Hemo I, Dou HL, Pines M, Vlodavsky I: Halofuginone: a potent inhibitor of critical steps in angiogenesis progression. FASEB J. 2000 Dec;14(15):2477-85. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/11099465"@en . . . . . . . . . . . . . . . . . . . . . . . . " "@en . . "23.8 to 72.1 hours"@en . " "@en . "Halofuginone is a potent inhibitor of collagen a1(I) and matrix metalloproteinase 2 (MMP-2) gene expression. Halofuginone also suppresses extracellular matrix deposition and cell proliferation. The profound antitumoral effect of halofuginone is attributed to its combined inhibition of the tumor stromal support, vascularization, invasiveness, and cell proliferation."@en . "investigational"@en .